In addition, there are currently 269 clinical trials registered on clinicaltrials.gov examining the use of PARP inhibitors as an anti-cancer therapy in chemo-resistant germline or somatic BRCA1/2 mutated breast, ovarian, lung, and pancreatic cancers (Dockery et al., 2017). Here, BRCA1 is linked to pancreatic neoplasm.